drugset / Trial / NCT05787535
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 TCR-T cell for HPV18 positive advanced solid tumor. The study will investigate DLT of HRYZ-T101 TCR-T cell injection.
Timeline
- Start
- 2023-03-21
- Primary completion
- 2025-02
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HRYZ-T101 | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | — |
| Background | Fludarabine | Small molecule | 25 mg/m2 | — |